BCC developing independently from BAP1-tumor predisposition syndrome in a patient with bilateral uveal melanoma: Diagnostic challenges to identify patients with BAP1-TPDS

Ocular Oncology

Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients with Uveal Melanoma Treated with Proton Beam Therapy

Int J Radiat Oncol Biol Phys.

Lee HJ Jr, Stacey A, Klesert TR, Wells C, Skalet A, Bloch C, Fung A, Bowen SR, Wong TP, Shibata D, Halasz LM, Rengan R

doi: 10.1016/j.ijrobp.2019.02.005.

Ocular Oncology

Intraocular Metastasis in Unilateral Multifocal Uveal Melanoma Without Melanocytosis or Germline BAP1 Mutations

JAMA Ophthalmol.

Durante MA, Walter SD, Paez-Escamilla M, Tokarev J, Decatur CL, Dubovy SR, Schefler AC, Harbour JW

doi: 10.1001/jamaophthalmol.

Ocular Oncology

Genetic Analysis of Uveal Melanoma in 658 Patients Using the Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D

Ophthalmology.

Vichitvejpaisal P, Dalvin LA, Mazloumi M, Ewens KG, Ganguly A, Shields CL

doi: 10.1016/j.ophtha.2019.04.027.

Ocular Oncology

Multi-Modality Analysis Improves Survival Prediction in Enucleated Uveal Melanoma Patients

Invest Ophthalmol Vis Sci.

Drabarek W, Yavuzyigitoglu S, Obulkasim A, van Riet J, Smit KN, van Poppelen NM, Vaarwater J, Brands T, Eussen B, Verdijk RM, Naus NC, Mensink HW, Paridaens D, Boersma E, van de Werken HJG, Kilic E, de Klein A, for the Rotterdam Ocular Melanoma Study Group.

doi: 10.1167/iovs.18-24818.

Ocular Oncology

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Eur J Cancer.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C

doi: 10.1016/j.ejca.2017.05.038.

Ocular Oncology

Estimation of the timing of BAP1 mutation in uveal melanoma progression

Sci Rep

Uner OE, See TRO, Szalai E, Grossniklaus HE, Stålhammar G

doi: 10.1038/s41598-021-88390-6

Ocular Oncology

Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients

Clin Exp Ophthalmol.

Yang X, Dalvin LA, Mazloumi M, Chang M, Shields JA, Mashayekhi A, Shields CL

doi: 10.1111/ceo.13758.

Ocular Oncology

Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma

Am J Ophthalmol.

Cai L, Paez-Escamilla M, Walter SD, Tarlan B, Decatur CL, Perez BM, Harbour JW

doi: 10.1016/j.ajo.2018.07.045.

Uveitis

Development of revised diagnostic criteria for Fuchs' uveitis syndrome in a Chinese population

Br J Ophthalmol

Yang P, Zhang W, Chen Z, Zhang H, Su G, Cao Q, Zhu Y, Zhong Z, Zhou C, Wang Y, Kijlstra A

doi: 10.1136/bjophthalmol-2021-319343

Related content

Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients with Uveal Melanoma Treated with Proton Beam Therapy

Intraocular Metastasis in Unilateral Multifocal Uveal Melanoma Without Melanocytosis or Germline BAP1 Mutations

Genetic Analysis of Uveal Melanoma in 658 Patients Using the Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D

Multi-Modality Analysis Improves Survival Prediction in Enucleated Uveal Melanoma Patients

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Estimation of the timing of BAP1 mutation in uveal melanoma progression

Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients

Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma

Development of revised diagnostic criteria for Fuchs' uveitis syndrome in a Chinese population